Results 21 to 30 of about 23,011 (205)
CD30: CD30 Ligand Interactions in the Immune Response
Autoimmunity, 2001 (2001). CD30: CD30 Ligand Interactions in the Immune Response. Autoimmunity: Vol. 33, No. 1, pp. 45-60.
S, Opat, J S, Gaston
openaire +2 more sources
Lymphomatoid papulosis: a practical review for pathologists [PDF]
Journal of Pathology and Translational MedicineLymphomatoid papulosis (LyP) is a primary cutaneous CD30+ lymphoproliferative disorder characterized by a chronic and self-healing recurrent cluster of erythematous papules or nodules on the skin of the trunk and/or extremities.
Mario L. Marques-Piubelli +2 more
doaj +1 more source
Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling. [PDF]
PLoS ONE, 2012 The TNF-receptor superfamily member CD30 is expressed on normal and malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells. CD30 transmits multiple effects, including activation of NF-κB signaling, cell proliferation, growth arrest ...
Sarah L Buchan, Aymen Al-Shamkhani
doaj +1 more source
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement [PDF]
Journal of Clinical and Diagnostic Research, 2015 Anaplastic lymphoma kinase (ALK) positive Anaplastic large cell lymphoma (ALCL) represents approximately 2% of all Non-Hodgkin’s lymphomas that commonly involves nodal as well as a wide variety of extra nodal sites, as skin, soft tissue, bones and lungs,
Smeeta Gajendra +4 more
doaj +1 more source
Клиническая онкогематология, 2021 Background. Pathomorphological analysis of lymph node tissues in immune-mediated lymphadenopathies commonly presupposes differential diagnosis with tumors of lymphoid and myeloid tissues with partial lesions in lymph nodes.
Alla Mikhailovna Kovrigina
doaj +1 more source
Frontiers in Immunology, 2017 CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin’s disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans. A limited number of studies have assessed the
Angela C. Zhou +3 more
doaj +1 more source
Clonal composition and differentiation stage of human CD30+ B cells in reactive lymph nodes
Frontiers in Immunology, 2023 IntroductionNormal CD30+ B cells represent a distinct B-cell differentiation stage with features of strong activation. We lack an in depth understanding of these cells, because they are not present in peripheral blood and are typically very rare in ...
Ralf Küppers +4 more
doaj +1 more source
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
Haematologica, 2013 Peripheral T-cell lymphoma, not otherwise specified is a heterogeneous group of aggressive neoplasms with indistinct borders. By gene expression profiling we previously reported unsupervised clusters of peripheral T-cell lymphomas, not otherwise ...
Bettina Bisig +9 more
doaj +1 more source
CD30 Ligand/CD30 Plays a Critical Role in Th17 Differentiation in Mice [PDF]
The Journal of Immunology, 2010 Abstract A CD30 ligand (CD30L; CD153) and its receptor, CD30, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily. These were expressed preferentially by activated CD4+T cells. In this paper, we show that CD44lowCD62hiCD4+ T cells from CD30L−/− or CD30−/− mice exhibited impaired differentiation ...
Xun, Sun +6 more
openaire +2 more sources
Molecular Oncology, 2018 CD30 is a 120‐kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large‐cell lymphoma (ALCL).
Rong Wang +6 more
doaj +1 more source